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ABSTRACT:  Operationally simple stereocontrolled semi-syntheses of the anti-cancer rotenoids 
elliptone and 12aβ-hydroxyelliptone, isolated from Derris elliptica and Derris trifoliata 
respectively, are described. Inspired by the work of Singhal, elliptone was prepared from 
rotenone via a dihydroxylation-oxidative cleavage, chemoselective Baeyer-Villiger oxidation, 
and acid-catalysed elimination sequence. Elaboration of elliptone to 12aβ-hydroxyelliptone was 
achieved via a diastereoselective chromium-mediated Étard-like hydroxylation. The semi-
synthesis of elliptone constitutes an improvement over previous methods in terms of safety, 
scalability, and yield, while the first synthesis of 12aβ-hydroxyelliptone is also described. 
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Natural rotenoids form the bioactive constituents of many traditional plant preparations used for 
crop protection and fishing in tropical parts of the world.1,2 As powerful inhibitors of 
mitochondrial respiration, there has been a steady increase in the number of rotenoids being 
investigated as potential anticancer agents.3,4 The most abundant and well-characterised members 
of the rotenoid family, rotenone (1), rotenolone (2), deguelin (3), and tephrosin (4) (Figure 1) 
have been shown to be nanomolar-active inhibitors of mitochondrial Complex I and we suggest 
this finding may explain their well-documented anticancer activities.3,4     
First isolated from Derris elliptica by Harper in 1939,5 elliptone (5) (Figure 1) represents one of 
the many natural rotenoids whose biological activity remains, in our view, underexplored.4a,6 
Isolated from Derris trifoliata by Ito in 2004,6 12aβ-hydroxyelliptone (6) (Figure 1) was found, 
alongside elliptone (5), to possess cancer chemopreventive properties comparable to those of β-
carotene; however, despite these promising results no further biological studies have been 
reported to date.6   
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Figure 1. The structures of the rotenoids rotenone (1), rotenolone (2), deguelin (3), tephrosin (4), 
elliptone (5), and 12aβ-hydroxyelliptone (6). 
As part of an extensive investigation into the chemistry and biochemistry of the natural rotenoids 
underway in our laboratory, we sought efficient, operationally simple semi-synthetic routes to 
elliptone (5) and 12aβ -hydroxyelliptone (6) from inexpensive rotenone (1). Our preference for 
semi-synthesis over total synthesis originated from a desire to obtain enantiomerically pure 
rotenoids in the shortest and most scalable of sequences possible.  
Previous efforts towards elliptone (5) have been restricted to a lengthy total synthesis of the 
racemic form, reported by Fukami in 1965,7 and two semi-syntheses of the natural enantiomer 
from derivatives of rotenone (1), described by Anzeveno and Singhal in 1979 and 1982 
respectively.8,9 In contrast, no synthesis of 12a-hydroxyelliptone (6) has been reported to date.  
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RESULTS AND DISCUSSION 
In evaluating the two reported semi-syntheses of elliptone (5) it was noted that the Anzeveno 
route suffered from a low overall yield,8a involved the use of many hazardous reagents and 
solvents, and proceeded via an intermediate lactol 7 (Scheme 1), accessed via an oxidative 
cleavage of rot-2'-enonic acid (8),8b that proved particularly susceptible to degradation in our 
hands. Additionally, the preparation of lactol 7 required a high (7.5 mol%) loading of highly 
toxic and expensive osmium tetroxide catalyst.8a The Singhal route seemed to be more appealing, 
proceeding via the stable lactol acetate 9 (Scheme 1) accessed by chemoselective Baeyer-Villiger 
oxidation of the known norketone 10.9 However, this short publication lacked experimental 
conditions, procedures, and characterisation data, and we were unable to successfully recreate 
the key Baeyer-Villiger chemistry using the reported meta-chloroperoxybenzoic acid (see also 
below).9a 
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Scheme 1. A comparison of the semi-syntheses of elliptone (6) reported by Anzeveno8a and 
Singhal9a and our proposed hydroxylation of elliptone (5) to 12aβ-hydroxyelliptone (6). 
Inspired by the chemistry of Singhal,9a an alternative preparation of the lactol acetate (9) from 
rotenone (1) was sought, anticipating that formal elimination of the acetoxy group under acidic 
conditions would indeed deliver elliptone (5) in a concise manner. Building upon the success of 
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the previous semi-synthesis of tephrosin (4),10 we reasoned that chromium-mediated Étard-like 
hydroxylation of elliptone (5) would provide 12aβ-hydroxyelliptone (6) as a single 
diastereoisomer (Scheme 1). 
Dihydroxylation of rotenone (1) with 0.4 mol% OsO4 in the presence of excess citric acid11 
provided the diastereoisomeric vic-diols (11) of amorphigenol in an excellent yield of 92%. 
Next, the oxidative cleavage of the vic-diols (11) with aqueous periodic acid provided the 
corresponding rotenone 6'-norketone (10) in an overall yield of 72% over two steps (Scheme 2). 
Importantly, both the dihydroxylation and oxidative cleavage reactions could be carried out on a 
multi-gram scale without any notable decrease in yield. 
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Scheme 2. Reagents and Conditions: a) OsO4 (0.4 mol%), NMO, citric acid, acetone: H2O (4:1), 
rt, 22 h, 92%; b) H5IO6, H2O, rt, 4.5 h, 78%; c) Oxone, MeCN: H2O (10:1), rt, 28 h, 35%; d) 
PTSA, toluene, 80 oC, 1.5 h, 76%; e) K2Cr2O7, HOAc: H2O (2:1), 60 oC, 0.5 h then rt, 18 h, 63%. 
The subsequent chemoselective Baeyer-Villiger reaction of the norketone (10) was more 
challenging. The use of traditional oxidants such as meta-chloroperoxybenzoic acid,9a peracetic 
acid, and trifluoroperacetic acid, proved unproductive with reactions suffering variously from 
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incomplete conversion of the norketone (10) or the formation of complex mixtures of 
unidentifiable polar by-products. More encouraging results were obtained using Oxone,12 the 
potassium peroxymonosulfate-containing triple salt, which afforded the mono-oxygenated lactol 
acetate (9) as the only identifiable product. Variations in the amount of Oxone employed, the 
reaction temperature, and the inclusion of either weakly acidic or basic additives were next to be 
investigated with a view to improving both the yield and rate of the reaction. Ultimately, 
however, the lactol acetate (9) could only be isolated in modest yields of 35-38% upon treatment 
of the norketone (10) with 8.0 equivalents of Oxone under neutral conditions. Complete 
consumption of the substrate was observed after 28 hours by LCMS, analysis by TLC 
complicated by the highly similar retention factors of starting material and product. Although 
low yielding the reaction could readily be performed on larger scales, providing sufficient 
material for the elimination step. 
Treatment of the lactol acetate (9) with para-toluenesulfonic acid in toluene at 80 oC proceeded 
smoothly to afford elliptone (5) in 76% yield.9a Pleasingly, the Étard-like hydroxylation of 
elliptone (5) with K2Cr2O7 in aqueous HOAc afforded 12aβ-hydroxyelliptone (6) in 63% yield as 
a single diastereoisomer. The stereochemical outcome of this reaction may be attributed to the 
pericyclic ene and [2,3] sigmatropic rearrangement steps of the Étard reaction,10 in conjunction 
with the ‘butterfly-wing’ architecture of the substrate. 
In conclusion, we have developed operationally simple four and five-step semi-syntheses of 
elliptone (5) and 12aβ-hydroxyelliptone (6) from rotenone (1). Also described is the preparation 
of elliptone (5), improving upon the methods of Anzeveno8 and Singhal9 in terms of scalability 
and yield.  Dihydroxylation of rotenone (1) followed by oxidative cleavage provided norketone 
(10), which was susceptible to chemoselective Baeyer-Villiger oxidation with excess Oxone to 
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afford lactol acetate (9).9 Acid-catalysed elimination according to Singhal’s procedure afforded 
elliptone (5).9 A highly diastereoselective Étard-like hydroxylation of elliptone (5) gave 12aβ-
hydroxyelliptone (6), the mechanistic details of which we have discussed previously.10 With the 
desired natural products in hand biological investigations are ongoing and the results will be 
reported in due course. 
EXPERIMENTAL SECTION 
General Experimental Procedures. Melting points for crystalline compounds were 
obtained using a Büchi Melting Point B-545 melting point apparatus. Optical rotations were 
recorded on an Anton-Paar MCP 100 polarimeter. [α]D values are reported in 10-1 deg cm2 g-1 at 598 
nm, concentration (c) is given in g(100 mL)-1. Infrared spectra were recorded on a Perkin-Elmer 
Spectrum One spectrometer. 1H and 13C NMR spectra were recorded on a Bruker Avance 500 
Cryo Ultrashield (500 MHz) spectrometer. Low-resolution mass spectra (LRMS) were recorded 
using an LCMS system (Agilent series LC with an ESCi Multi-Mode Ionisation Waters ZQ 
spectrometer using MassLynx 4.1 software). High-resolution mass spectra (HRMS) were 
recorded using a Micromass Q-TOF. Thin layer chromatography retention factors (Rf) are quoted 
to the nearest 0.05. Flash column chromatography was carried out according to the method of 
Still.14 Yields refer to chromatographically and spectroscopically pure compounds, for which full 
analytical data are given. (6aS,12aS,5'R)-Rotenone (1) (95% purity) was purchased from 
Molekula Fine Chemicals as an off-white amorphous solid and was crystallised from EtOH (x3) 
to give colourless plates [m.p. 162-163 oC, (lit. 163 oC)].13 All other solvents and reagents were 
used as obtained from commercial sources. 
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The (trivial) nomenclature and numbering systems used for the assignments in this manuscript 
are well established in this natural product family.1c,1d,13 See also Figure 2: 
 
Figure 2. Representative atom numbering schemes for rotenone (1) and lactol acetate (9), from 
which all products in this study derive. 
(6aS,12aS,5'R,6'R)- and (6aS,12aS,5'R,6'S)-Amorphigenol (11) 
A solution of OsO4 (420 μL, 0.041 mmol, 2.5 weight % in t-BuOH) was added in one portion to 
a solution of (6aS,12aS,5'R)-rotenone (1) (4.00 g, 10.2 mmol), N-methylmorpholine-N-oxide 
(1.43 g, 12.2 mmol) and citric acid (7.80 g, 40.6 mmol) in acetone (160 mL) and H2O (40 mL). 
The mixture was stirred at room temperature for 22 h. EtOAc (200 mL) was added followed by a 
saturated aq Na2SO3 solution (200 mL) and the two phases were mixed vigorously for 0.5 h. The 
organic layer was separated, washed with H2O (3 × 200 mL) and brine (200 mL), dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. The crude pale yellow solid was 
crystallised from MeOH-H2O (approximately 1:1) to afford a 55:45 unassigned diastereoisomeric 
mixture of (6aS,12aS,5'R,6'S)- and (6aS,12aS,5'R,6'R)-amorphigenol (11) as white needles (3.98 
g, 92%). 
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m.p. 181-184 oC; Rf 0.05 (n-hexane-EtOAc; 1:1); [α]D20 -89 (c 0.1 in CHCl3); vmax (neat)/cm-1 3600-
3200 br, 1668m (C=O)ketone, 1604m, 1515m, 1348m, 1317m, 1287m, 1214m, 1201m, 1181m, 
1058m, 1009m, 909m, 816m; 
NMR data for the major diastereoisomer: δH (500 MHz, CDCl3) 1.21 [3H, s, C(8')H3], 2.29 [1H, 
dd, J 10.0, 5.0 Hz, C(7')HH'OH], 2.40 [1H, s, C(6')OH], 3.18 [1H, app d, J 12.0 Hz, C(4')HH'], 
3.18 [1H, app d, J 12.0, Hz, C(4')HH'], 3.52 [1H, ddd, J 14.0, 10.0, 5.0 Hz, C(7')HH'OH], 3.73 
[1H, ddd, J 14.0, 10.0, 5.0 Hz, C(7')HH'OH], 3.76 [3H, s, C(2')H3], 3.81 [3H, s, C(3')H3], 3.84 
[1H, d, J 4.5 Hz, C(12a)H], 4.18 [1H, app d, J 15.0 Hz, C(6)HH'], 4.61 [1H, dd, J 15.0, 3.5 Hz, 
C(6)HH'], 4.86 [1H, app t, J 12.0 Hz, C(5')H], 4.93 [1H, ddd, J 4.5, 3.5, 1.0 Hz, C(6a)H], 6.45 
[1H, s, C(4)H], 6.47 [1H, d, J 11.0 Hz, C(10)H], 6.75 [1H, s, C(1)H], 7.82 [1H, d, J 11.0 Hz, 
C(11)H]; δC (125 MHz, CDCl3) 19.3 [C(8')H3], 27.0 [C(4')H2], 44.6 [C(12a)H], 55.9 [C(3')H3], 
56.3 [C(2')H3], 66.2 [C(6)H2], 66.8 [C(7')H2], 72.2 [C(6a)H], 73.4 [C(6')], 87.3 [C(5')H], 100.9 
[C(4)H], 104.6 [C(10)H], 104.7 [C(13)], 110.3 [C(1)H], 113.4 [C(8)], 113.5 [C(11a)], 129.9 
[C(11)H], 143.9 [C(2)], 147.4 [C(4a)], 149.5 [C(3)], 157.9 [C(7a)], 166.9 [C(9)], 189.0 [C(12)]; 
NMR data for the minor diastereoisomer: δH (500 MHz, CDCl3) 1.17 [3H, s, C(8')H3], 2.09 [1H, 
dd, J 10.0, 5.0 Hz, C(7')HH'OH], 2.55 [1H, s, C(6')OH], 3.16 [1H, dd, J 19.5, 12.0 Hz, 
C(4')HH'], 3.23 [1H, dd, J 19.5, 12.0 Hz, C(4')HH'], 3.56 [1H, ddd, J 14.0, 10.0, 5.0 Hz, 
C(7')HH'OH], 3.76 [3H, s, C(2')H3], 3.80 [1H, ddd, J 14.0, 10.0, 5.0 Hz, C(7')HH'OH], 3.81 [3H, 
s, C(3')H3], 3.85 [1H, d, J 4.5 Hz, C(12a)H], 4.18 [1H, app d, J 15.0 Hz, C(6)HH'], 4.62 [1H, dd, 
J 15.0, 4.0 Hz, C(6)HH'], 4.86 [1H, app t, J 12.0 Hz, C(5')H], 4.93 [1H, ddd, J 4.5, 3.5, 1.0 Hz, 
C(6a)H], 6.45 [1H, s, C(4)H], 6.47 [1H, d, J 11.0 Hz, C(10)H], 6.75 [1H, s, C(1)H], 7.83 [1H, d, 
J 11.0 Hz, C(11)H]; δC (125 MHz, CDCl3) 19.7 [C(8')H3], 27.3 [C(4')H2], 44.6 [C(12a)H], 55.9 
[C(3')H3], 56.3 [C(2')H3], 66.2 [C(6)H2], 68.6 [C(7')H2], 72.2 [C(6a)H], 72.9 [C(6')], 90.0 
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[C(5')H], 100.9 [C(4)H], 104.6 [C(10)H], 104.8 [C(13)], 110.3 [C(1)H], 113.3 [C(8)], 113.7 
[C(11a)], 129.9 [C(11)H], 143.9 [C(2)], 147.4 [C(4a)], 149.5 [C(3)], 157.9 [C(7a)], 166.6 [C(9)], 
189.0 [C(12)]; 
LRMS m/z found 429.2, C23H25O8 [M+H]+ requires 429.2; HRMS m/z found 451.1354, C23H24O8Na 
[M+Na]+ requires 451.1363. 
(6aS,12aS,5'R)-Rotenone-6'-norketone (10) 
A diastereomeric mixture of (6aS,12aS,5'R,6'R)- and (6aS,12aS,5'R,6'S)-amorphigenol (11) (2.00 
g, 4.67 mmol) was added in one portion to a solution of periodic acid (4.26 g, 18.7 mmol) in H2O 
(200 mL). The suspension was stirred vigorously at room temperature for 4.5 h before it was 
extracted with EtOAc (4 × 80 mL). The combined organic extracts were washed with brine (100 
mL), dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude off-white solid 
was crystallised from MeOH to afford (6aS,12aS,5'R)-rotenone-6'-norketone (10) as white 
needles (1.44 g, 78%). m.p. 194-196 oC (lit. m.p. 198-199 oC)9b; Rf 0.20 (n-hexane-EtOAc; 1:1); 
[α]D20 -60 (c 0.1 in CHCl3) (no lit. value); vmax (neat)/cm-1 2910w, 1714 (C=O)ketone, 1681 (C=O)ketone, 
1607m, 1514m, 1457m, 1349m, 1305m, 1254m, 1238m, 1215m, 1196m, 1145m, 1092m, 
1005m, 910m, 818m; δH (500 MHz, CDCl3) 2.30 [3H, s, C(8')H3], 3.33 [1H, dd, J 16.0, 10.0 Hz, 
C(4')HH'], 3.36 [1H, dd, J 16.0, 10.0 Hz, C(4')HH'], 3.76 [3H, s, C(2')H3], 3.81 [3H, s, C(3')H3], 
3.86 [1H, d, J 4.0 Hz, C(12a)H], 4.18 [1H, d, J 12.0 Hz, C(6)HH'], 4.61 [1H, dd, J 12.0, 3.0 Hz, 
C(6)HH'], 4.93 [1H, dd, J 4.0, 3.0 Hz, C(6a)H], 5.13 [1H, m, C(5')H], 6.45 [1H, s, C(4)H], 6.58 
[1H, d, J 8.5 Hz, C(10)H], 6.74 [1H, s, C(1)H], 7.87 [1H, d, J 8.5 Hz, C(11)H]; δC (125 MHz, 
CDCl3) 26.3 [C(8')H3], 29.3 [C(4')H2], 44.6 [C(12a)H], 55.9 [C(3')H3], 56.3 [C(2')H3], 66.2 
[C(6)H2], 72.4 [C(6a)H], 87.3 [C(5')H], 100.9 [C(4)H], 104.5 [C(13)], 105.0 [C(10)H], 110.3 
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[C(1)H], 111.9 [C(8)], 114.0 [C(11a], 130.3 [C(11)H], 143.9 [C(2)], 147.4 [C(4a)], 149.6 [C(3)], 
157.9 [C(7a)], 166.3 [C(9)], 188.9 [C(12)], 206.7 [C(6')]; LRMS m/z found 397.1, C22H21O7 
[M+H]+ requires 397.1; HRMS m/z found 397.1295, C22H21O7 [M+H]+ requires 397.1287. 
Lactol Acetate (9) 
Oxone (6.21 g, 20.2 mmol) was added in one portion to a solution of (6aS,12aS,5'R)-rotenone-6'-
norketone (10) (1.00 g, 2.53 mmol) in MeCN (60.0 mL) and H2O (6.0 mL). The mixture was 
stirred at room temperature for 28 h. Saturated aq NaHCO3 solution (100 mL) was added 
followed by EtOAc (100 mL) and the two phases were mixed vigorously for 0.5 h. The organic 
layer was separated, washed with brine (100 mL), dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude pale yellow solid was purified by flash column 
chromatography (n-hexane-EtOAc; 3:1) to afford lactol acetate (9) as a white amorphous solid, 
which crystallised from MeOH as white needles (360 mg, 35%). m.p. 193-194 oC (no lit. value)9a; 
Rf 0.20 (n-hexane-EtOAc; 2:1) (after two elutions); [α]D20 -294 (c 0.1 in CHCl3) (no lit. value)9a; vmax 
(neat)/cm-1 2935w, 1754m (C=O)ester, 1670m  (C=O)ketone, 1601m, 1510m, 1458m, 1346m, 1251m, 
1214m, 1192m, 1171m, 1050m, 913m, 816m; δH (500 MHz, CDCl3) 2.10 [3H, s, C(9')H3], 3.12 
[1H, dd, J 10.5, 1.5 Hz, C(4')HH'], 3.39 [1H, dd, J 10.5, 8.5 Hz, C(4')HH'], 3.76 [3H, s, C(2')H3], 
3.79 [3H, s, C(3')H3], 3.87 [1H, d, J 4.0 Hz, C(12a)H], 4.18 [1H, d, J 12.0 Hz, C(6)HH'], 4.62 
[1H, dd, J 12.0, 3.0 Hz, C(6)HH'], 4.97 [1H, app t, J 4.0 Hz, C(6a)H], 6.44 [1H, s, C(4)H], 6.60 
[1H, d, J 8.5 Hz, C(10)H], 6.73 [1H, s, C(1)H], 6.84 [1H, dd, J 8.5, 1.5 Hz, C(5')H], 7.88 [1H, d, 
J 8.5 Hz, C(11)H]; δC (125 MHz, CDCl3) 21.0 [C(8')H3], 32.7 [C(4')H2], 44.7 [C(12a)H], 55.9 
[C(3')H3], 56.3 [C(2')H3], 66.2 [C(6)H2], 72.5 [C(6a)H], 99.4 [C(5')H], 100.9 [C(4)H], 104.4 
[C(13)], 105.4 [C(10)H], 110.2 [C(1)H], 111.1 [C(8)], 114.4 [C(11a)], 130.1 [C(11)H], 143.9 
[C(2)], 147.4 [C(4a)], 149.6 [C(3)], 157.8 [C(7a)], 165.0 [C(9)], 169.6 [C(7')], 189.1 [C(12)]; 
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LRMS m/z found 413.1, C22H21O8 [M+H]+ requires 413.1; HRMS m/z found 413.1249, C22H21O8 
[M+H]+ requires 413.1236. 
(6aS,12aS)-Elliptone (5) 
para-Toluenesulfonic acid monohydrate (36.9 mg, 0.194 mmol) was added to a solution of lactol 
acetate 9 (400 mg, 0.971 mmol) in dry toluene (40.0 mL) under an atmosphere of nitrogen. The 
mixture was heated at 80 oC for 1.5 h, cooled to room temperature, and diluted with EtOAc (40 
mL). Saturated aq NaHCO3 solution (20 mL) was added and the two phases were mixed 
vigorously for 0.5 h. The organic layer was separated, washed with H2O (20 mL) and brine (20 
mL), dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude off-white solid 
was purified by flash column chromatography (n-hexane-EtOAc; 2:1) to afford (6aS,12aS)-
elliptone (5) as a white amorphous solid (259 mg, 76%). Rf 0.25 (n-hexane-EtOAc; 2:1); [α]D20 
+46 (c 0.1 in CHCl3); vmax (neat)/cm-1 1679m (C=O)ketone, 1613m, 1596w, 1514m, 1464m, 1388m, 
1333m, 1214m, 1193m, 1090m, 913m, 820m; δH (500 MHz, CDCl3) 3.75 [3H, s, C(2')H3], 3.79 
[3H, s, C(3')H3], 3.94 [1H, d, J 4.0 Hz, C(12a)H], 4.24 [1H, d, J 12.0 Hz, C(6')HH'], 4.72 [1 H, 
dd, J 12.0, 3.0 Hz, C(6)HH'], 5.08 [1H, ddd, J 4.0, 3.0, 1.0 Hz, C(6a)H], 6.46 [1H, s, C(4)H], 
6.76 [1H, s, C(1)H], 6.92 [1H, d, J 2.5 Hz, C(5')H], 7.14 [1H, d, J 8.5 Hz, C(10)H], 7.56 [1H, d, 
J 2.5 Hz, C(4')H], 7.89 [1H, d, J 8.5 Hz, C(11)H]; δC (125 MHz, CDCl3) 44.7 [C(12a)H], 55.9 
[C(3')H3], 56.3 [C(2')H3], 66.2 [C(6)H2], 72.9 [C(6a)H], 101.0 [C(4)H], 104.5 [C(13)], 104.9 
[C(5')H], 106.7 [C(10)H], 110.3 [C(1)H], 113.6 [C(8)], 117.2 [C(11a)], 124.0 [C(11)H], 143.9 
[C(2)], 145.0 [C(4')H], 147.4 [C(4a)], 149.6 [C(3)], 156.0 [C(7a)], 160.3 [C(9)], 189.9 [C(12)]; 
LRMS m/z found 353.1, C20H17O6 [M+H]+ requires 353.1; HRMS m/z found 375.0826, C20H16O6Na 
[M+Na]+ requires 375.0839. 
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(6aR,12aR)-12aβ-Hydroxyelliptone (6) 
A solution of K2Cr2O7 (79.0 mg, 0.269 mmol, 0.94 equiv.) in H2O (1.0 mL) was added dropwise 
over a period of 2 min to a solution of (6aS,12aS)-elliptone (5) (100 mg, 0.284 mmol) HOAc (2.0 
mL) at 60  ̊C. The mixture was stirred at 60 ̊C for 30 min, cooled to room temperature, and 
stirred for an additional 18 h. H2O (20 mL) was added to the dark-green mixture and the resulting 
suspension was stirred vigorously for 30 min while an off-white precipitate formed, which was 
collected by filtration, washed with H2O (10 mL), and dried in vacuo overnight. The crude 
precipitate was purified by flash column chromatography (n-hexane-EtOAc; 2:1) to afford 
(6aR,12aR)-12aβ-hydroxyelliptone (6) as a white amorphous solid (66.0 mg, 63%). Rf 0.15 (n-
hexane-EtOAc; 2:1); [α]D20 -5 (c 0.1 in CHCl3); vmax (neat)/cm-1 3600-3300 br, 2970w, 1739 
(C=O)ketone, 1680w, 1613m, 1509m, 1464m, 1366m, 1216m, 1203m, 1080m, 1025m, 813m, 743m; 
δH (500 MHz, CDCl3) 3.72 [3H, s, C(2')H3], 3.80 [3H, s, C(3')H3], 4.47 [1H, s, C(6a)H], 4.56 [1H, 
d, J 12.0 Hz, C(6)HH'], 4.73 [1H, d, J 12.0 Hz, C(6)HH'], 4.75 [1H, s, C(12a)OH], 6.49 [1H, s, 
C(4)H], 6.55 [1H, s, C(1)H], 6.91 [1H, d, J 2.5 Hz, C(5')H], 7.17 [1H, d, J 8.5 Hz, C(10)H], 7.57 
[1H, d, J 2.5 Hz, C(4')H], 7.88 [1H, d, J 8.5 Hz, C(10)H]; δC (125 MHz, CDCl3) 55.9 [C(3')H3], 
56.4 [C(2')H3], 63.8 [C(6)H2], 67.7 [C(12a)OH], 76.7 [C(6a)H], 101.1 [C(4)H], 104.8 [C(5')H], 
107.1 [C(10)H], 108.4 [C(13)], 109.2 [C(1)H], 112.0 [C(11a)], 117.3 [C(8)], 123.9 [C(11)H], 
144.0 [C(2)], 145.1 [C(4')H], 148.4 [C(4a)], 151.2 [C(3)], 155.8 [C(7a)], 160.6 [C(9)], 192.2 
[C(12)]; LRMS m/z found 351.1, C20H17O7 [M+H]+ requires 351.1; HRMS m/z found 391.0800, 
C20H16O7Na [M+Na]+ requires 391.0793. 
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*Stable intermediates
*Operationally simple
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